PMID- 34140793
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 1178-7015 (Print)
IS  - 1178-7015 (Electronic)
IS  - 1178-7015 (Linking)
VI  - 14
DP  - 2021
TI  - Evaluation of Cannula Safety in Injection of Poly-L-Lactic Acid.
PG  - 615-622
LID - 10.2147/CCID.S305479 [doi]
AB  - BACKGROUND AND OBJECTIVE: Poly-L-lactic acid (PLLA) has been used in various 
      medical applications for decades, including aesthetic ones. The use of a cannula 
      technique in injecting PLLA has been proposed in order to lower the incidence 
      rate of adverse events (AEs) following treatment. Such AEs include nodule 
      formation, which may occur less frequently by fanning the product with a cannula, 
      thus creating a more uniform product placement compared to that resulting from 
      the use of a needle. Currently, however, there is a lack of comparative research 
      regarding the safety of cannulas versus needles for PLLA injections, as the 
      selection of either remains highly subjective. Therefore, the objective of our 
      study was to investigate the safety of cannula use in the administration of PLLA, 
      in order to report safety outcomes. MATERIALS AND METHODS: A single-center, 
      retrospective chart review was conducted to examine the data of patients who had 
      previously undergone treatment with PLLA in the form of Sculptra((R)) Aesthetic in 
      the face and/or neck regions. Twenty-seven subject charts met eligibility. 
      Descriptive data regarding treatment and follow-up visits were collected and 
      analyzed. RESULTS: A total of seven AEs resulted from eighty-two treatment 
      sessions (8.54%), with 6/27 patients having experienced at least one AE (22.22%). 
      Mild bruising was the most commonly reported AE (57.14%). The majority of the AEs 
      were mild and transient in nature, with one moderate AE being a nodule that was 
      possibly related to a concomitant treatment. All AEs were resolved with follow-up 
      care. CONCLUSION: Mild AEs such as bruising, swelling and pain should be expected 
      following the use of a cannula for PLLA injections. However, the incidence rates 
      of AEs following treatment can remain low if proper product preparation and 
      treatment techniques are utilized.
CI  - (c) 2021 Nikolis et al.
FAU - Nikolis, Andreas
AU  - Nikolis A
AUID- ORCID: 0000-0002-9056-4998
AD  - Division of Plastic Surgery, McGill University Health Center, Montreal, QC, 
      Canada.
AD  - Erevna Innovations Clinical Research Unit, Montreal, QC, Canada.
FAU - Avelar, Luiz E
AU  - Avelar LE
AD  - Department of Forensic Anthropology, Civil Police Department, Minas Gerais, 
      Brazil.
AD  - Private Practice, Belo Horizonte, Brazil.
FAU - Enright, Kaitlyn M
AU  - Enright KM
AD  - Erevna Innovations Clinical Research Unit, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20210610
PL  - New Zealand
TA  - Clin Cosmet Investig Dermatol
JT  - Clinical, cosmetic and investigational dermatology
JID - 101543449
PMC - PMC8203184
OTO - NOTNLM
OT  - adverse events
OT  - antiaging
OT  - cannula
OT  - injection techniques
OT  - poly-L-lactic acid
COIS- Dr Andreas Nikolis reports grants and personal fees from Galderma, Merz and 
      Allergan, outside the submitted work. The authors report no other conflicts of 
      interest in this work.
EDAT- 2021/06/19 06:00
MHDA- 2021/06/19 06:01
PMCR- 2021/06/10
CRDT- 2021/06/18 06:40
PHST- 2021/02/08 00:00 [received]
PHST- 2021/03/27 00:00 [accepted]
PHST- 2021/06/18 06:40 [entrez]
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2021/06/19 06:01 [medline]
PHST- 2021/06/10 00:00 [pmc-release]
AID - 305479 [pii]
AID - 10.2147/CCID.S305479 [doi]
PST - epublish
SO  - Clin Cosmet Investig Dermatol. 2021 Jun 10;14:615-622. doi: 10.2147/CCID.S305479. 
      eCollection 2021.